Lorenzo Pasquali

Lorenzo Pasquali

Auto-generated profile, based on publicly available information

Lorenzo Pasquali

Endocrine Regulatory Genomics Lab, University Pompeu Fabra, 08003 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2020 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
DEDecio Eizirik
Decio Eizirik
LPLorenzo Pasquali
Lorenzo Pasquali
MCMiriam Cnop
Miriam Cnop

12 January 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LPLorenzo Pasquali
Lorenzo Pasquali
KGKyle J Gaulton
Kyle J Gaulton
SRSantiago A Rodríguez-Seguí
Santiago A Rodríguez-Seguí
LMLoris Mularoni
Loris Mularoni
IMIrene Miguel-Escalada
Irene Miguel-Escalada
JFJorge Ferrer
Jorge Ferrer
Jorge Ferrer and colleagues have mapped regulatory SNP variants associated in GWAS with type 2 diabetes risk and glycemic traits to large clusters of enhancer elements regulating the transcriptional identity of pancreatic β cells via a highly connected transcription factor network. Type 2 diabetes affects over 300 million people, causing severe complications and premature death, yet the underlying molecular mechanisms are largely unknown. Pancreatic islet dysfunction is central in type 2 diabetes pathogenesis, and understanding islet genome regulation could therefore provide valuable mechanistic insights. We have now mapped and examined the function of human islet cis-regulatory networks. We identify genomic sequences that are targeted by islet transcription factors to drive islet-specific gene activity and show that most such sequences reside in clusters of enhancers that form physical three-dimensional chromatin domains. We find that sequence variants associated with type 2 diabetes and fasting glycemia are enriched in these clustered islet enhancers and identify trait-associated variants that disrupt DNA binding and islet enhancer activity. Our studies illustrate how islet transcription factors interact functionally with the epigenome and provide systematic evidence that the dysregulation of islet enhancers is relevant to the mechanisms underlying type 2 diabetes.

31 January 2010 in Nature Genetics
Verified
Journal Article
Open access
PDF file
KGKyle J Gaulton
Kyle J Gaulton
TNTakao Nammo
Takao Nammo
LPLorenzo Pasquali
Lorenzo Pasquali
JSJeremy M Simon
Jeremy M Simon
PGPaul G Giresi
Paul G Giresi
JFJorge Ferrer
Jorge Ferrer
Jorge Ferrer, Jason Lieb, and Karen Mohlke and colleagues identify regulatory DNA active in human pancreatic islets by formaldehyde-assisted isolation of regulatory elements (FAIRE) coupled with high-throughput sequencing. They identified 80,000 open chromatin sites and 3,300 islet-selective open chromatin sites and found that a TCF7L2 intronic variant associated with type 2 diabetes is located in islet-selective open chromatin. Tissue-specific transcriptional regulation is central to human disease1. To identify regulatory DNA active in human pancreatic islets, we profiled chromatin by formaldehyde-assisted isolation of regulatory elements2,3,4 coupled with high-throughput sequencing (FAIRE-seq). We identified ∼80,000 open chromatin sites. Comparison of FAIRE-seq data from islets to that from five non-islet cell lines revealed ∼3,300 physically linked clusters of islet-selective open chromatin sites, which typically encompassed single genes that have islet-specific expression. We mapped sequence variants to open chromatin sites and found that rs7903146, a TCF7L2 intronic variant strongly associated with type 2 diabetes5, is located in islet-selective open chromatin. We found that human islet samples heterozygous for rs7903146 showed allelic imbalance in islet FAIRE signals and that the variant alters enhancer activity, indicating that genetic variation at this locus acts in cis with local chromatin and regulatory changes. These findings illuminate the tissue-specific organization of cis-regulatory elements and show that FAIRE-seq can guide the identification of regulatory variants underlying disease susceptibility.

1 October 2012 in Cell Metabolism
Verified
Journal Article
Closed access
IMIgnasi Morán
Ignasi Morán
IAİldem Akerman
İldem Akerman
MBMartijn van de Bunt
Martijn van de Bunt
RXRuiyu Xie
Ruiyu Xie
MBMarion Benazra
Marion Benazra
JFJorge Ferrer
Jorge Ferrer

9 November 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCthe DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium
the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium
KGKyle J Gaulton
Kyle J Gaulton
TFTeresa Ferreira
Teresa Ferreira
YLYeji Lee
Yeji Lee
ARAnne Raimondo
Anne Raimondo
AMAndrew P Morris
Andrew P Morris
Kyle Gaulton, Mark McCarthy, Andrew Morris and colleagues report fine mapping and genomic annotation of 39 established type 2 diabetes susceptibility loci. They find that the set of potential causal variants is enriched for overlap with FOXA2 binding sites in human islet and liver cells, and they show that a likely causal variant near MTNR1B increases FOXA2-bound enhancer activity, providing a molecular mechanism to explain the effect of this locus on disease risk. We performed fine mapping of 39 established type 2 diabetes (T2D) loci in 27,206 cases and 57,574 controls of European ancestry. We identified 49 distinct association signals at these loci, including five mapping in or near KCNQ1. 'Credible sets' of the variants most likely to drive each distinct signal mapped predominantly to noncoding sequence, implying that association with T2D is mediated through gene regulation. Credible set variants were enriched for overlap with FOXA2 chromatin immunoprecipitation binding sites in human islet and liver cells, including at MTNR1B, where fine mapping implicated rs10830963 as driving T2D association. We confirmed that the T2D risk allele for this SNP increases FOXA2-bound enhancer activity in islet- and liver-derived cells. We observed allele-specific differences in NEUROD1 binding in islet-derived cells, consistent with evidence that the T2D risk allele increases islet MTNR1B expression. Our study demonstrates how integration of genetic and genomic information can define molecular mechanisms through which variants underlying association signals exert their effects on disease.

27 April 2015 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
ICInês Cebola
Inês Cebola
SRSantiago A. Rodríguez-Seguí
Santiago A. Rodríguez-Seguí
CCCandy H-H. Cho
Candy H-H. Cho
JBJose Bessa
Jose Bessa
MRMeritxell Rovira
Meritxell Rovira
JFJorge Ferrer
Jorge Ferrer
The genomic regulatory programmes that underlie human organogenesis are poorly understood. Pancreas development, in particular, has pivotal implications for pancreatic regeneration, cancer and diabetes. We have now characterized the regulatory landscape of embryonic multipotent progenitor cells that give rise to all pancreatic epithelial lineages. Using human embryonic pancreas and embryonic-stem-cell-derived progenitors we identify stage-specific transcripts and associated enhancers, many of which are co-occupied by transcription factors that are essential for pancreas development. We further show that TEAD1, a Hippo signalling effector, is an integral component of the transcription factor combinatorial code of pancreatic progenitor enhancers. TEAD and its coactivator YAP activate key pancreatic signalling mediators and transcription factors, and regulate the expansion of pancreatic progenitors. This work therefore uncovers a central role for TEAD and YAP as signal-responsive regulators of multipotent pancreatic progenitors, and provides a resource for the study of embryonic development of the human pancreas.